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Abstract: Renal cell carcinoma (RCC) is a malignant tumor associated with various tumor microen-
vironments (TMEs). The immune system is activated by the development of cancer and drives
T cell anti-tumor response. CD8 T cells are known to improve clinical outcomes and sensitivity to
immunotherapy, and play a crucial role against tumors. In contrast, tumor-associated macrophages
(TAMs) suppress immunity against malignancy and lead to tumor progression. TAMs are promoted
from damaged TMEs and mount proinflammatory responses to pathogens. Initial immunotherapy
consists of interferon-α and interleukin-2. However, response to such therapy is unclear in most
patients, and it is associated with high levels of toxicity. Immune checkpoint inhibitors (ICIs), which
up-regulate immune responses by blocking the programed cell death protein 1 (PD-1) receptor,
the ligand of PD-1, or cytotoxic T-lymphocyte-associated protein 4 T cells, have led to a new era
of immunotherapy. Furthermore, combination strategies with ICIs have proven effective through
several randomized controlled trials. We expect the next generation of immunotherapy to lead to
better outcomes based on ongoing trials and inspire new therapeutic strategies.
Keywords: biomarkers; clinical trials; immune checkpoint inhibitor; immunotherapy; renal cell carci-
noma
1. Introduction
Renal cell carcinoma (RCC) is the most common type of kidney malignancy, con-
stituting 2–3% of all cancers. This nephron-arising neoplasm consists of heterogenous
subgroups according to histologic and molecular subtypes. Clear cell RCC (ccRCC) is an
aggressive subtype, constituting 70–80% of all RCCs [1]. Von Hippel-Lindau (VHL) is a
crucial component for maintaining the oxygen homeostasis of the cellular environment [2].
The loss of the VHL tumor suppressor drives the hypoxic pathway by hypoxia-inducible
factors (HIF) transcription factors. It activates several hypoxia-driven genes, such as vas-
cular endothelial growth factor (VEGF), and subsequently induces angiogenesis and cell
growth [3,4]. This VHL mutation course is the main pathway of ccRCC. Modifications
of various genes similarly manifest as other types of RCC. Papillary RCC is the second
most common subtype of RCC, and is classified into two subtypes: type I, which is mainly
associated with MET alterations, and type II, which is associated with the NRF2-antioxidant
response component [5]. Chromophobe RCC is associated with mutations of TP53 and
PTEN, while translocation RCC is associated with fusions of TFE3 or TFEB genes [6,7].
Decades ago, there were few options for systemic therapy in advanced RCC. Cytokine
therapy, represented by interleukin-2 (IL-2) and interferon alfa (IFN-α), showed some
benefits in a few advanced patients with RCC, but only proved efficacy in a limited
proportion of patients [8]. Moreover, cytokine therapy is associated with a high level
of toxicity, which limited its general use. With advances in genomic research by the
Cancer Genome Atlas (TCGA), targeted molecular therapeutics, specifically tyrosine kinase
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inhibitors (TKIs) targeting the VEGF receptor pathway, have now replaced cytokine therapy
and are widely used as first- or second-line therapy. The development of the TCGA also
led to a better understanding of the mammalian target of the rapamycin (mTOR) pathway
that is known to induce cell growth and division in ccRCC [3,9]. Subsequent development
and use of mTOR inhibitors have shown similar oncological outcomes to TKIs [10–12].
Immunity against malignancy varies depending on several components that make
up the tumor microenvironment (TME), and therefore clinical symptoms and the course
of treatment differ accordingly. RCC is classified as an immunogenic tumor based on its
response to immunotherapy, the incidence of spontaneous regression, and a high level
of tumor T cell infiltration [13]. Recent advances in immune checkpoint inhibitor (ICI)
therapy up-regulating immune responses by blocking the programed cell death protein 1
(PD-1) receptor, ligand of PD-1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4
(CTLA-4), and T cells have overtaken cytokine-based regimens and are now key players in
the field of immunotherapy [14,15]. Unlike IFN-α and IL-2, for which only a limited range
of patients are eligible due to toxicity, ICIs are characterized by superior safety profiles and
oncological efficacy. Recently, updated guidelines recommend combining VEGF targeted
agents with ICIs depending on patient performance and comorbidity.
Risk stratification systems are essential for selecting the optimal treatment for a specific
patient. Unfortunately, there are no predictive biomarkers for RCC, which limits effective
strategies for management. Current international guidelines for risk stratification rely on
clinical variables to guide prognosis and treatment selection. The Memorial Sloan Kettering
Cancer Center (MSKCC) criteria incorporate five prognosticators: low performance status,
high level of serum dehydrogenase, high level of serum calcium, low concentration of
hemoglobin, and interval less than one year from diagnosis to treatment [16]. The Inter-
national Metastatic Renal Cell Carcinoma Database Consortium (IMDC) utilizes similar
prognosticators to those of MSKCC but includes high levels of neutrophil and platelet
counts instead of serum lactate dehydrogenase level [17,18]. Patients without any corre-
sponding prognostic factors are classified into a low-risk group, patients with one or two
prognosticators into an intermediate-risk group, and three or more into a poor-risk group.
In this comprehensive review, we will discuss up-to-date evidence on the microenvi-
ronments involved in the development of RCC and how treatment strategies targeted at
the host immune system are feasible for controlling disease progression. We summarize
progress made regarding systemic treatment, from the cytokine therapy era to the treatment
utilizing combined ICIs with or without targeted therapies. Lastly, we summarize ongo-
ing trials involving immunotherapies that will change the landscape of future systemic
therapies targeted at advanced RCC.
2. Tumor Microenvironment in Renal Cell Carcinoma
Chromosome 3p loss is the first genetic event characterizing sporadic ccRCC, followed
by VHL mutation [19]. VHL negatively regulates HIF 1/2α, which reduce oxygen demand
in the cellular environment by increasing glycolytic flux and reducing oxidative phos-
phorylation. This pathway induces oxygen supply by hyper-vascularization. Based on
metabolic pathway analysis by RNA sequencing, ccRCC is known to possess high levels of
metabolites during glycolysis and to reduce levels of metabolites associated with oxidative
phosphorylation [20]. Hyper-vascularity and the immune system are not independent, and
treatment targeting the VEGF receptor promotes the immune pathway by modifying the
aberrant blood supply [21].
TME are complicated, containing transformed cells and immune infiltrates. Tumor-
infiltrating cells promote or inhibit cancer activity according to the type of cancer. The
immune system is activated by cancer development and drives T cell anti-tumor response
by suppressing tumor cells directly, modulating various anti-tumor responses, facilitating
the emerging memorial system, and preparing specificity for tumor-derived proteins [8].
T cell activation, according to immunotherapy response, is a core component in the prog-
nosis of ccRCC. CD8 T cells play a crucial role in combating malignant tumors and are
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associated with favorable clinical outcomes and response to immunotherapy [22–26]. Pre-
sentation of major histocompatibility class I (MHC-I) molecules on cancer cells helps
T cell receptors recognize antigens. This pathway activates CD8 T cells, which subse-
quently activates antigen-specific immune response, and directly removes antigen-bearing
cells [27]. The antigen-presenting machinery (APM) promoted by activated CD8 T cells
is a component that interlinks antigens and MHC-I. Upregulation of APM genes refers
to the increased production of antigen-presentation and the number of T cells. CcRCC is
characterized by the highest T cell infiltration and immune infiltration when compared to
other malignancies. The immunogenicity of ccRCC is related to MHC-I and APM gene
expression, which may potentially serve as indicators of response to PD-1 inhibitors. The
promotion of APM expression is a unique feature of ccRCC [28]. In contrast, Th2 and
regulatory T cells are negatively associated with prognosis. An abundant environment
with Th2 and regulatory T cells suppresses the immune response and is associated with
the tumor mutation load [28].
Macrophages are phagocytic innate immune cells that regulate responses to tissue
damage. Macrophages are promoted based on consecutive signals from the damaged
microenvironment and mount proinflammatory responses to pathogens [29]. Macrophages
are abundantly observed in growing cancer cells and mediate lymphocyte trapping accord-
ing to interactions with CD8 T cells in tumor stroma. Cytokines and chemokines expressed
by tumor-associated macrophages (TAMs) suppress immunity against malignancy and
lead to tumor progression [30]. In an in vivo study, the efficiency of T cells increased when
TAMs were depleted by pexidartinib, a small molecule tyrosine kinase inhibitor that acts
against colony-stimulating factor 1. The depletion of TAMs not only increased the number
of tumor-infiltrating CD8 T cells but also improved their migration and ability to reach
cancer cells [31–33].
Tertiary lymphoid structures (TLS) are a lymphoid environment usually associated
with reactions to infection or inflammation [34]. TLS neogenesis is induced by chronic
bacterial or viral infection or by chronic inflammatory diseases such as multiple sclerosis,
Sjögren’s syndrome, or allograft rejection [35–39]. TME is similar to TLS and includes
several components associated with the immune system and T cell activation. Mature
dendritic cells (DCs), which are associated with activated CD8 T cells within the TLS, are
associated with favorable survival outcomes in ccRCC. On the other hand, DCs outside
of TLS are associated with poor survival outcomes in response to dysfunctional CD8
T cells [40,41].
The wide variety of clinical features and outcomes of immunotherapy in patients
with ccRCC are due to the heterogeneity of TME. A study that utilized mass cytometry
confirmed the subsets of T cells and TAMs, the critical components of TME [42]. In a
study comparing 73 patients with ccRCC and five healthy controls, 20 T cell phenotypes
and 17 TAMs phenotypes were identified. With ongoing research on the mechanisms of
treatment failure, TME heterogeneity is being perceived as a key factor.
3. Immunotherapy in the Early Era
Late recurrence after partial or radical nephrectomy, long-term stabilization of disease
without systemic treatment, and, in rare cases, spontaneous regression suggest that the
mechanisms of the host immune system are keystones of controlling tumor growth or
suppression [43–46].
IFN-α has been the primary agent used in the early immunotherapy era. The overall
response rate to IFN-α has been reported to be low as 12% [43]. Patients with visceral
metastatic RCC, particularly lung RCC, or with prior nephrectomy showed more favorable
survival outcomes [47,48]. However, maintenance of response was restricted to less than
two years [43].
Patients treated with high-dose IL-2 exhibit 4% complete response (CR), 8% partial
response, and 23 months of response duration. Moreover, high-dose IL-2 was related
to severe cardiovascular toxicity due to increased vascular permeability, with treatment-
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related death occurring in 4% of patients [49,50]. Although oncological outcomes with
IFN-α or IL-2 are often dramatic in selected patients, most patients experienced no apparent
survival benefit. Hence, these agents are not considered as first- or second-line therapy
unless the patient has excellent performance status with normal organ function [8].
Combination therapy consisting of IFN-α and bevacizumab was studied in several
trials. Patients with metastatic RCC without previous treatment received IFN-α plus
bevacizumab or IFN-α with placebo. Progression-free survival (PFS) was superior in the
combination treatment arm. However, no significant improvements were observed in
overall survival (OS) during the study period [51–54].
4. Immune-Associated Novel Prognosticators of Renal Cell Carcinoma
Recent genomic studies of RCC have developed an understanding of tumor hetero-
geneity [3,55,56]. Much progress has been made in revealing the relationships between
the immune system and tumors, but immunotherapy responses differ in each case. Even
within a specific type of cancer, a subset of patients will show strong immune infiltration,
while others show little or no response to immunotherapy. This heterogeneity suggests that
pathological classification alone is insufficient to predict treatment effect and prognosis. A
more detailed sub-classification system is warranted [56,57].
Long non-coding RNAs (lncRNAs) are predictors that have become an important
focus of debate in recent years [58,59]. LncRNAs are non-protein coding RNAs longer
than 200 nucleotides [60,61] that are involved in tumor development and suppression by
regulating the immune system [62–65]. LncRNAs are more tumor-specific than protein-
coding RNAs, inducing up-regulated RCC carcinogenesis, promoting progression and
metastasis with a positive-feedback loop [66].
Khadirnaikar et al. found 143 immune-associated lncRNAs genes related to RCC by
examining 2378 genes in TCGA RNA sequence data [67]. They divided gene samples into
three groups (C1, C2, and C3) by K-means consensus clustering according to the expression
levels of immune lncRNAs. In a classification according to immune cluster, C3 showed a
significantly higher grade of tumor and metastasis and thus poorer prognosis than other
groups. These immune clusters yielded better survival prediction rates than those using
miRNA or mRNA. The analysis showed increased CD8 T cells and decreased DCs in the
C3 cluster when compared to other groups. Patients with C3 showed higher CD8 T cell
infiltration; however, they had a worse prognosis due to lack of DC, which plays a role in
T cell activation. On the other hand, in C1 and C2, naïve B cell and neutrophil infiltration
associated with a better prognosis were higher than C3 [68,69]. Immune infiltration is
different depending on the expression level of lncRNAs, which may explain the differences
in prognosis.
Molecular subsets of RCC have been redefined according to differential clinical re-
sponses to angiogenesis blockade with or without ICI [70,71]. Motzer et al. performed
transcriptomic analysis of advanced RCC tumor samples, which revealed seven subsets
with distinct angiogenesis, immune, cell-cycle, metabolism, and stromal programs. Clinical
benefits with sunitinib and atezolizumab plus bevacizumab were observed in patients with
high angiogenesis, while atezolizumab plus bevacizumab was beneficial in patients with
high T-effector and/or cell-cycle transcription [57]. Overall, the results implied that RCC
may be molecularly classified to stratify patients for the optimal oncological outcome.
5. Immune Checkpoint Inhibitors for Renal Cell Carcinoma
Blockades of immune checkpoint components such as PD-1/PD-L1 and CTLA-4 have
shown considerable oncological benefit and have shifted treatment strategies targeted at
RCC. Clinical trials involving ICIs are summarized in Table 1.
CheckMate 025 was a phase III, open-label, randomized study that compared nivolumab
with everolimus. A total of 821 patients with advanced ccRCC who had received previous
anti-angiogenic therapy were randomly allocated to receive nivolumab (3 mg/kg) every
two weeks or everolimus (10 mg) daily [72]. The median OS was favorable for nivolumab
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when compared to everolimus (25.0 months vs. 19.6 months; HR 0.73; 98.5% confidence
interval [CI] 0.57–0.93; p = 0.002). The objective response rate (ORR) was also superior in the
nivolumab arm (25% vs. 5%; 95% CI 3.68–9.72; p < 0.001). However, PFS was comparable
in both treatment arms (4.6 months vs. 4.4 months; HR 0.88; 95% CI 0.75–1.03; p = 0.11).
Superior quality-of-life (QoL) was observed in patients treated with nivolumab, with fewer
treatment-related adverse events (TRAEs) of grade 3 or 4 (19% vs. 37%) [73].
Sunitinib and pazopanib are common first-line agents used for patients with advanced
RCC. The recent development of combination treatments with ICIs is changing treatment
paradigms, especially for intermediate-risk or poor-risk patients. CheckMate 214 was a
phase III study that compared nivolumab and ipilimumab with sunitinib for patients with
treatment-naïve advanced ccRCC [74]. A total of 1096 patients were allocated at a 1:1 ratio
to nivolumab (3 mg/kg) every two weeks and ipilimumab (1 mg/kg) every three weeks or
sunitinib (50 mg) daily for four weeks (6-week cycle). In patients with intermediate-risk or
poor-risk group by the IMDC criteria, the median OS was not reached in the combination
group, while 26 months was achieved in the sunitinib group (HR 0.63; p < 0.001). The
ORR was superior in the combination group compared to the sunitinib group a 42% versus
27% (p < 0.001). CR rates were also favorable in the combination group compared to the
sunitinib group (9% vs. 1%; p < 0.001). Median PFS was improved with combination
therapy (11.6 months vs. 8.4 months; HR 0.82; p = 0.03); however, it did not satisfy the
prespecified statistical threshold (alpha level = 0.009). Grade 3 or 4 TRAEs were observed
in 46% of the patients in the nivolumab and ipilimumab combination group, while 63% of
the patients in the sunitinib group. The patients were administered FKSI-19 questionnaires
to access health-related QoL, which revealed that the combination arm experienced more
significant improvement from baseline than the sunitinib arm (p < 0.001). ORR was lower
in the combination arm than the sunitinib arm (29% vs. 52%; p < 0.001). Median PFS was
also inferior in the combination arm than in the sunitinib arm (15.3 months vs. 25.1 months;
HR for progressive disease or death, 2.18; 99.1% CI, 1.29–3.68; p < 0.001).
IMmotion151 was a phase III, open-label, randomized study that compared ate-
zolizumab plus bevacizumab with sunitinib for chemotherapy-naïve advanced RCC pa-
tients with clear cell or sarcomatoid pathology [75,76]. A total of 915 patients were ran-
domly allocated at a 1:1 ratio to atezolizumab (1200 mg) and bevacizumab (15 mg/kg)
every three weeks or sunitinib (50 mg) daily for four weeks (6-week cycle). Overall, 40% of
the patients exhibited PD-L1 expression, with more than 1% in tumor-infiltrating immune
cells. In PD-L1 positive patients, the median PFS was superior in the combination arm
compared to the sunitinib arm (11.2 months vs. 7.7 months; HR 0.74; 95% CI 0.57–0.96;
p = 0.022). The intention-to-treat (ITT) cohort exhibited similar favorable results in the com-
bination arm (11.2 months vs. 8.4 months; HR 0.83; 95% CI 0.70–0.97; p = 0.022). However,
median OS was comparable in both PD-L1 positive (HR 0.84; 95% CI 0.62–1.15; p = 0.286)
and in ITT patients (HR 0.93; 95% CI 0.76–1.14; p = 0.475) in the second interim analysis.
In subgroup analyses, PD-L1 positive patients who were administered atezolizumab plus
bevacizumab exhibited superior PFS regardless of MSKCC and IMDC risk classification
criteria. Previous nephrectomy and the absences of liver metastasis and sarcomatoid histol-
ogy were factors associated with favorable PFS in the combination arm. ORR was superior
with atezolizumab plus bevacizumab (43%) than with sunitinib (35%) in PD-L1 positive
patients. The rate of CR was comparable between the combination versus the sunitinib
arms (9% vs. 4%). Grade 3 or 4 TRAEs were noted in 40% of patients in the combination
arm and 54% of patients in the sunitinib arm.
JAVELIN Renal 101 also involved a combination of ICIs as the first-line of therapy [77].
This phase III trial involved 886 patients with treatment-naïve advanced RCC and ran-
domized patients at a 1:1 ratio to compare avelumab (10 mg/kg) every two weeks plus
axitinib (5 mg) twice daily with sunitinib (50 mg) once daily for four weeks (6-week cycle).
In the PD-L1 positive patients, the median PFS was favorable for avelumab plus axitinib
compared to sunitinib (13.8 months vs. 7.2 months; HR 0.61; 95% CI 0.47–0.79; p < 0.001).
The ORR in the avelumab and axitinib group was higher than that of the sunitinib group
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in both the PD-L1 positive group and the overall group (55.2% vs. 25.5% and 51.4% vs.
25.7%, respectively). The rate of CR was also higher in the combination group in both the
PD-L1 positive group and in the overall group (12% vs. 6% and 15% vs. 8%, respectively).
TRAEs appeared in 99.5% of patients who received avelumab plus axitinib, but in 99.3% of
patients who received sunitinib. More patients needed subsequent therapy after sunitinib
compared to combination therapy (39.2% vs. 20.8%).
Table 1. Phase III clinical trials investigating combination immune checkpoint inhibitor therapies for advanced renal
cell carcinoma.
Trial Agents Clinical Setting OS (Months) PFS (Months) ORR (%) TRAEs (%) *
CheckMate 025 [72] Nivolumab vs. Everolimus Second-line
25.0 vs. 19.6 4.6 vs. 4.4 25.0 vs. 5.0
19.0 vs. 37.0(p = 0.002) (p = 0.11) (p < 0.001)





Not reached vs. 26.0 11.6 vs. 8.4 42.0 vs. 27.0
46.0 vs. 63.0
(p < 0.001) (p = 0.03)
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of patients who received sunitinib. More patients needed subsequent therapy after 
sunitinib compared to combination therapy (39.2% vs. 20.8%). 
KEYNOTE-426 was a phase III study t at compared pembrolizumab plus axitinib 
with sunitinib. A total of 861 patients with chemotherapy-naïve, advanced RCC were ran-
domly allocated at a 1:1 ratio to receive pembrolizumab (200 mg) every three weeks with 
axitinib (5 mg) twice daily or sunitinib (50 mg) daily for four weeks (6-week cycle) [78]. 
The estimated survival rate at 12 months was 89.9% in the pembrolizumab plus axitinib 
arm and 78.3% in the sunitinib arm. The median survival was not reached in both arms; 
however, the possibility of death was significantly lower in the combination therapy arm 
(HR 0.53; 95% CI 0.38–0.74; p < 0.001). The me ian PFS was four months longer in the 
pembrolizumab and axitinib arm than in the sunitinib arm (15.1 months vs. 11.1 months; 
HR 0.69; 95% CI 0.57–0.84; p < 0.001). The survival advantages of pembrolizumab plus 
axitinib were observed regardless of IMDC risk classification and PD-L1 expression. The 
ORR and CR were superior in the combination arm compared to the sunitinib arm (59.3% 
vs. 35.7%; p < 0.001 and 5.8% vs. 1.9%, respectively). Subsequent chemotherapy was 
needed in 50.0% of patients in the pembrolizumab plus axitinib arm and in 60.7% of the 
patients in the sunitinib arm. TRAEs were observed in 96.3% of the patients in the pem-
brolizumab-axitinib arm and 97.6% of the patients in the sunitinib arm. Notably, the rate 
of grade 3 or higher TRAEs was higher in the pembrolizumab-axitinib arm than the 
sunitinib arm (62.9% vs. 58.1%). An extended study with a median follow-up of 30.6 
Not significant per the pres ecified alpha level 9 threshold. † Not estimated at the
second interim analysis. ‡ The stratified odds ratio 3.73. ITT, intention-to-treatment; ORR, objective response rate; OS, overall survival;
PD-L1, programed death-ligand 1; PFS, progression-free survival; TRAEs, treatment-related adverse events.
KEYNOTE-426 was a phase III study that compared pembrolizumab plus axitinib
with sunitinib. A total of 861 patients with chemotherapy-naïve, advanced RCC were
randomly allocated at a 1:1 ratio to rec ive pe rolizumab (200 mg) every three we ks
with axitinib (5 mg) twice daily or sunitinib (50 mg) daily for four weeks (6-week cycle) [78].
The esti at survival rate at 12 months was 89.9% in the pe brolizumab plus axitinib
arm and 78.3% in the sun tinib arm. The median survival was not reach d in both arms;
howev r, the possibility of d ath was significantly lower in the combination therapy arm
(HR 0.53; 95% CI 0.38–0.74; p < 0.001). The median PFS was four months longer in the
pembrolizumab and axitinib arm than in the sunitinib arm (15.1 months vs. 11.1 months;
HR 0.69; 95% CI 0.57–0.84; p < 0.001). The sur ival advantages of pembrolizumab plus
axitinib were observed regardless of IMDC risk classification and PD-L1 expression. The
ORR and CR were superior in the combination arm compared to the sunitinib arm (59.3% vs.
35.7%; p < 0.001 and 5.8% vs. 1.9%, respectively). Subsequent chemotherapy was needed in
50.0% of patients in the pembrolizumab plus axitinib arm and in 60.7% of the patients in the
sunitinib arm. TRAEs were observed in 96.3% of the patients in the pembrolizumab-axitinib
arm and 97.6% of the patients in the sunitinib arm. Notably, the rate of grade 3 or higher
TRAEs was higher in the pembrolizumab-axitinib arm than the sunitinib arm (62.9% vs.
58.1%). An extended study with a median follow-up of 30.6 months also showed benefits
in the pembrolizumab plus axitinib combination arm [71]. The OS was not reached in the
pembrolizumab-axitinib arm, while 35.7 months was observed in the sunitinib arm within
the ITT population (HR 0.68; 95% CI 0.55–0.85; p < 0.001). In this extended exploratory
analysis, patients with favorable-risk based on the IMDC criteria showed no difference in
OS (HR 1.06; 95% CI 0.60–1.86; p = 0.58), while patients with intermediate-risk or poor-risk
showed significant benefit (HR 0.63; 95% CI 0.50–0.81; p < 0.001).
6. Ongoing Trials Involving Immune Checkpoint Inhibitors
Several phase III clinical trials involving ICIs are ongoing and are expecting results [79].
A summary of these ongoing trials is presented in Table 2.
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Table 2. Ongoing phase III clinical trials investigating first-line therapies for advanced renal cell carcinoma.
Trial Identifier Comparing Agents Primary Endpoint
KEYNOTE-679/
ECHO-302 [80] NCT03260894 Pembrolizumab + Epacadostat vs. Sunitinib or Pazopanib ORR
CLEAR [81] NCT02811861 Lenvatinib + (Everolimus or Pembrolizumab) vs. Sunitinib PFS
CheckMate 9ER [82] NCT03141177 Nivolumab + Cabozantinib ± Ipilimumab vs. Sunitinib PFS
COSMIC-313 [83] NCT03937219 Cabozantinib + Nivolumab + Ipilimumab vs. Nivolumab +Ipilimumab PFS
PDIGREE [84] NCT03793166 Nivolumab + Ipilimumab→ Nivolumab + Cabozantinib vs.Nivolumab OS
CONTACT-03 [85] NCT04338269
(Atezolizumab or Avelumab or Nivolumab or
Pembrolizumab)→ PD→ Atezolizumab + Cabozantinib vs.
Cabozantinib
OS, PFS
CheckMate 914 [86] NCT03138512 Radial or partial nephrectomy→ Nivolumab ± Ipilimumabvs. Placebo DFS
NORDIC-SUN [87] NCT03977571
Cytoreductive nephrectomy + Nivolumab + Ipilimumab→
Nivolumab vs. No surgery + Nivolumab + Ipilimumab→
Nivolumab
OS
PROSPER RCC [88] NCT03055013 Radical or partial nephrectomy + perioperative Nivolumabvs.Radial or partial nephrectomy only PFS
RAMPART [89] NCT03288532 Radical or partial nephrectomy→ (Active monitoring vs.Durvalumab vs. Durvalumab + Tremelimumab) DFS, OS
DFS; disease-free survival, ORR, objective response rate; PD, progressive disease; PFS, progression-free survival.
KEYNOTE-679/ECHO-302 is a phase III, open-label, randomized controlled trial
comparing pembrolizumab plus epacadostat with standard TKI treatment such as sunitinib
or pazopanib in patients with treatment-naïve, locally advanced or metastatic ccRCC
(NCT03260894) [80]. Patients of the combination therapy group receive pembrolizumab
(200 mg) intravenously every three weeks and epacadostat (100 mg) orally twice daily.
Standard-of-care patients receive sunitinib (50 mg) once daily for four weeks (6-week
cycle) or pazopanib 800 mg once daily. The primary endpoint is ORR, while the secondary
endpoints are safety and tolerability.
CLEAR is a phase III randomized study comparing lenvatinib in combination with
everolimus or pembrolizumab versus sunitinib alone in the first-line setting of advanced
RCC (NCT02811861) [81]. Patients who receive lenvatinib (18 mg) daily plus everolimus
(5 mg) daily or lenvatinib (20 mg) daily plus pembrolizumab (200 mg) every three weeks
are compared with patients who receive sunitinib (50 mg) once daily for four weeks (6-week
cycle). The primary endpoint is PFS, and the secondary endpoints are ORR, OS, TRAEs,
health-related QoL, and PFS until the next-line of therapy.
CheckMate 9ER is a phase III, open-label, randomized trial of nivolumab combined
with cabozantinib versus sunitinib in patients with previously untreated advanced or
metastatic RCC (NCT03141177) [82]. The primary endpoint is PFS, and the secondary
endpoints are OS, ORR, and TRAEs.
COSMIC-313 is a phase III, double-blind, randomized trial comparing cabozantinib
in combination with nivolumab and ipilimumab (four doses) versus nivolumab and ipili-
mumab (four doses) in patients with treatment-naïve, advanced or metastatic ccRCC of
intermediate-risk or poor-risk (NCT03937219) [83]. The primary endpoint is PFS, and the
secondary is OS.
PDIGREE is a phase III, open-label, randomized trial comparing nivolumab and ip-
ilimumab followed by nivolumab versus cabozantinib with nivolumab in patients with
untreated metastatic RCC (NCT03793166) [84]. Patients receive nivolumab and ipilimumab
intravenously every three weeks for up to four cycles. Patients with progressive disease re-
ceive cabozantinib daily until further disease progression or unacceptable toxicity. Patients
with CR continue nivolumab intravenously every four weeks. Patients with a non-CR and
non-progressive disease receive nivolumab intravenously every four weeks or nivolumab
every four weeks plus cabozantinib daily in the absence of disease progression or unac-
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ceptable toxicity. The primary endpoint is OS, and the secondary endpoints are PFS, CR,
ORR, TRAEs.
CONTACT-03 is a phase III, open-label, randomized trial to investigate the efficacy
and safety of atezolizumab plus cabozantinib versus cabozantinib monotherapy in patients
with inoperable, locally advanced, or metastatic RCC who exhibit radiographic tumor
progression during or after ICI treatment (NCT04338269) [85]. Patients with disease
progression after treatment of atezolizumab, avelumab, pembrolizumab, or nivolumab
receive atezolizumab (1200 mg) every three weeks with cabozantinib (60 mg) orally once
daily or cabozantinib alone. The primary endpoints are PFS and OS. Ongoing trials
associated with surgical treatments are summarized in Table 2 [86–89].
7. Summary and Future Directions
Advancements in ICIs have led to improved therapeutic efficacy and safety for various
types of tumors, including advanced RCC. The immune mechanisms underlying the
development and progression of RCC make ICIs the most valuable potential systemic
therapy in RCC management.
Early cytokine immunotherapy played an important role in the management of ad-
vanced RCC, but its high toxicity profile and low response rate limited its widespread use.
TKIs targeting the VEGF receptor pathway have made significant advancements in TKIs
without adverse events. Newly developed ICIs and their combined treatments have shown
favorable results in terms of oncological outcomes and safety profiles and are currently
recommended as first-line therapy.
Cytokines and chemokines expressed by TAMs suppress anti-tumor immune mecha-
nisms, leading to tumor progression [30,90,91]. Furthermore, TAMs are known strongly
associated with resistance to TKIs and ICIs. Specific pathways regulating the recruitment,
polarization, and metabolism of TAMs have been identified in preclinical studies [92].
Understanding TME is an important step in understanding immune mechanisms
involved in RCC development. TKI inhibits the process in which mutations of the VHL
gene induces HIF to accelerate VEGF for neovasculation and tumor development. Novel
approaches are underway to develop biomarkers associated with TAM and to integrate
novel radiomic modalities. Accumulation of mannosylated liposome containing fluorescent
dye in TAMs has been demonstrated in a mouse model of lung carcinoma [93]. This
indicates that mannose-coated liposomes combined with therapeutic agents could be
delivered to TME. A pilot study that quantified TAM using ferumoxytol-enhanced MRI
illustrated the possibility that TME could be accessed with modified MR technology [94].
New approaches and applications of functional and structural imaging for RCC are being
investigated, and are expected to be useful decision-making tools in the near future [95–97].
Recent trials have shown that combined ICI therapies are oncologically superior to
single-agent targeted therapies in terms of OS and PFS outcomes as well as TRAEs profiles.
Future studies are warranted to elucidate the optimal combination and sequencing of
these agents for maximal survival benefit. Further research on novel diagnostic modalities
remains to be performed.
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Abbreviations
APM antigen-presenting machinery
ccRCC clear cell renal cell carcinoma
CI confidence interval
CR complete response
CTLA-4 cytotoxic T-lymphocyte-associated protein 4
DC dendritic cell
HIF hypoxia-inducible factors
ICI immune checkpoint inhibitor
IFN-α interferon-alfa
IL-2 interleukin-2
IMDC International Metastatic Renal Cell Carcinoma Database Consortium
ITT intention-to-treat
lncRNA long non-coding RNA
MHC-I major histocompatibility class I
MSKCC Memorial Sloan Kettering Cancer Center
mTOR mammalian target of the rapamycin
ORR objective response rate
OS overall survival
PD-1 programed cell death protein 1




TCGA The Cancer Genome Atlas
TKI tyrosine kinase inhibitor
TLS tertiary lymphoid structures
TME tumor microenvironment
TRAEs treatment-related adverse events
VEGF vascular endothelial growth factor
VHL Von Hippel-Lindau
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